1-benzyl-1h-indazol-3-ol has been researched along with Methemoglobinemia in 1 studies
*Methemoglobinemia: The presence of methemoglobin in the blood, resulting in cyanosis. A small amount of methemoglobin is present in the blood normally, but injury or toxic agents convert a larger proportion of hemoglobin into methemoglobin, which does not function reversibly as an oxygen carrier. Methemoglobinemia may be due to a defect in the enzyme NADH methemoglobin reductase (an autosomal recessive trait) or to an abnormality in hemoglobin M (an autosomal dominant trait). (Dorland, 27th ed) [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruneau, P; Delvare, C; Edwards, MP; McMillan, RM | 1 |
1 other study(ies) available for 1-benzyl-1h-indazol-3-ol and Methemoglobinemia
| Article | Year |
|---|---|
Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity.
Topics: Administration, Oral; Animals; Chemical Phenomena; Chemistry; Dinoprostone; Dogs; Humans; Indazoles; Leukotriene B4; Lipoxygenase Inhibitors; Male; Methemoglobinemia; Methylation; Molecular Structure; Oxidation-Reduction; Rats; Rats, Inbred Strains; Stereoisomerism; Structure-Activity Relationship; Thromboxane B2 | 1991 |